Martin Čerňan
A5034072822- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Central Venous Catheters and Hemodialysis
- Protein Degradation and Inhibitors
- COVID-19 Impact on Reproduction
- Fungal Infections and Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Advanced biosensing and bioanalysis techniques
- Hematological disorders and diagnostics
- Respiratory viral infections research
- Eosinophilic Disorders and Syndromes
- Antifungal resistance and susceptibility
- T-cell and Retrovirus Studies
- Retinoids in leukemia and cellular processes
- Cancer-related cognitive impairment studies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cancer Immunotherapy and Biomarkers
- Cutaneous lymphoproliferative disorders research
- Histone Deacetylase Inhibitors Research
University Hospital Olomouc
2017-2024
Palacký University Olomouc
2017-2024
Hospital Universitario Puerta de Hierro Majadahonda
2023
Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics HM patients developing COVID-19 and analyzed predictors mortality. The survey was supported by the Scientific Working Group Infection Hematology European Association (EHA). Eligible analysis were adult laboratory-confirmed...
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and between January 2021 March 2022 were analyzed. A total 1548 cases included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing 753 (49%), the Omicron variant was prevalent (517, 68.7%). Most received ≤2 vaccine doses before (1419, 91%), mostly...
BackgroundThe COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, monoclonal antibodies have been effective the general population, their benefits these patients may not be as pronounced.MethodsThe EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers data from malignancy since pandemic's...
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent (20)19 disease (COVID-19)-related death. The changing epidemiological therapeutic scenarios suggest that there has been improvement in severity survival COVID-19 during the different waves pandemic general population, but this not investigated yet MM patients. Here we analyzed a large cohort 1221 patients with confirmed SARS-CoV-2...
Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) typically incur high rates of infections and both drugs comorbidities may modulate infection risk.The present study aims to assess the effect immunosuppressive agents on clinical outcomes MPN patients affected by coronavirus disease 2019 (COVID-19).This is an observational study.We specifically searched analyzed collected EPICOVIDEHA online registry, which includes individuals hematological malignancies diagnosed...
Summary Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first‐line venetoclax and azacitidine (VEN + AZA)‐treated acute myeloid leukaemias in Czech, Austrian Slovak haematology centres. Among 186 patients, 85 (46%) received prophylaxis, while 101 (54%) no prophylaxis. Fungal infections occurred 1/85 patients (1%) 5/101 (5%) ( p = 0.222). No significant difference was recorded between AFP terms...
Abstract Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate efficacy pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) 6-month follow-up preventing COVID-19 in adult patients hematology malignancy. Among 606 cohort, 96 (16%) contracted median 98.5 days after...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive behavior and poor prognosis. We present the first retrospective analysis mapping its incidence therapeutic outcomes in patients diagnosed treated from 2000 to 2017 Czech Republic. The cohort comprised 14 (10 males, 4 females) median age at diagnosis of 39 years (range, 5-68 years). Initially, skin involvement was noted 10 (71%) bone marrow infiltration 9 (64%). complete remission achieved...
Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these is limited. This study analyzed from the EPICOVIDEHA-EPIFLUEHA registry, focusing HM diagnosed during 2023-2024 autumn-winter season. The assessed epidemiology, clinical characteristics, risk factors, outcomes. examined 1312 Of these, 59.5% required hospitalization, 13.5%...
Background: COVID-19 treatment strategies for haematological malignancy patients are adapted from immunocompetent population, without solid evidence. We aimed to describe the efficacy of dexamethasone in a large cohort this population. Methods: Retrospective study multicentre EPICOVIDEHA registry on patients, diagnosed between May 2021 and January 2023. Patients receiving only were compared those plus antiviral strategies. A Cox regression was modelled detect factors associated with...
Coronavirus disease 2019 (COVID-19) represents an important infectious complication associated with high mortality rates in patients hematologic diseases. There have not been published any epidemiologic studies from Czech Republic so far.This study is the first analysis of malignancies and bone marrow failure syndromes treated at single hematology center between March 1 December 31, 2020, whom COVID-19 infection was confirmed.The sample comprised 96 aged 26 to 84 years (median, 66.0 years)....
Infectious complications during induction chemotherapy of acute myeloid leukaemia are very common. Prophylactic use antibiotics however is an ongoing challenge in this situation due to bacterial multi-drug resistance. The aim study was provide a comprehensive overview the incidence infectious patients with AML undergoing therapy using "7+3" protocol without routine antibiotic prophylaxis at one clinical site providing specialised haematological care Czech Republic, over period 15 years. also...
Vaccination is an important tool in the fight against COVID-19 pandemic patients with haematologic malignancies. The paper provides analysis of course breakthrough SARS-CoV-2 infection a group vaccinated haematological malignancy and comparison historical cohort 96 non-vaccinated malignancies bone marrow failure syndromes (two patients) treatment COVID-19. A severe or critical was significantly less frequent (10.2% vs. 31.4%, p = 0.003). need for hospitalisation due to lower (27.1% 72.6%, <...
Topic: 4. Acute myeloid leukemia - Clinical Background: At diagnosis, acute promyelocytic leukaemia (APL) is associated with high risk of bleeding complications due to coagulopathy and thrombocytopenia. In current guidelines, it explicitly stated that the introduction central venous catheter should be avoided in this initial phase. However, patients absolutely need high-quality access for administration both antitumor supportive treatment. A peripherally inserted (PICC) a intended medium...